Higher body weight in Chinese patients is associated with treatment resistance to fixed-dose IL-17 inhibition with ixekizumab but not to weight-adjusted secukinumab therapy

Supplemental material for: Higher body weight in Chinese patients is associated with treatment resistance to fixed-dose IL-17 inhibition with ixekizumab but not to weight-adjusted secukinumab therapy. This supplemental material includes additional analyses supporting the main findings of the study. Specifically, it contains: (1) Baseline characteristics of patients treated with ixekizumab and secukinumab (Table S1); (2) Restricted cubic spline analyses evaluating the association between body weight and treatment resistance at week 12 (Figure S1); (3) Multivariable logistic regression analyses using body weight instead of body mass index (Table S2); (4) Sensitivity analyses restricted to patients receiving secukinumab 300 mg (Figure S2). These data further support the robustness of the observed association between body weight and treatment resistance to fixed-dose IL-17 inhibition.